Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 2/20 | 0.36 |
| ▸ | ANPEP | P15144 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10222492 | 0.89 | FKBP1A (0.47) | SMN1; SMN2FKBP1ATP53POLBMMP2 | |
| SCHEMBL13008557 | 0.89 | FKBP1A (0.47) | SMN1; SMN2FKBP1ATP53POLBMMP2 | |
| SCHEMBL12670675 | 0.89 | FKBP1A (0.47) | SMN1; SMN2FKBP1ATP53POLBMMP2 | |
| SCHEMBL10222506 | 0.87 | FKBP1A (0.52) | SMN1; SMN2FKBP1APOLBCYP3A4ALDH1A1 | |
| SCHEMBL12604254 | 0.79 | MMP2 (0.42) | SMN1; SMN2FKBP1AMMP2ANPEPCYP3A4 | |
| SCHEMBL19271791 | 0.77 | HTT (0.39) | MAPTHTT | |
| SCHEMBL5702246 | 0.77 | LMNA (0.40) | POLBMAPTKDM4EHTT | |
| SCHEMBL19487470 | 0.77 | HTT (0.39) | MAPTHTT | |
| SCHEMBL5702250 | 0.77 | LMNA (0.40) | POLBMAPTKDM4EHTT | |
| SCHEMBL12312731 | 0.77 | LMNA (0.40) | POLBMAPTKDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1057894-B1 | Esterase genes and uses of the same | SUMITOMO CHEMICAL CO (JP) | 2010-04-28 | — | — | EP | disclosed |
| EP-1316610-B1 | Preparation comprising an enzyme for asymmetrical hydrolysis of N-substituted C3-C4 cyclic imino-2-carboxylic acid ester and method of using the same | SUMITOMO CHEMICAL CO (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-6936445-B2 | Enzyme preparation and method of using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-08-30 | — | — | US | disclosed |
| US-6812008-B2 | NUCLEOTIDE SEQUENCES CODING POLYPEPTIDE FOR USE IN THE GENERATION OF S-N-BENZYLAZETIDINE-2-CARBOXYLIC ACID | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-11-02 | — | — | US | disclosed |
| US-20030124683-A1 | Enzyme preparation and method of using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-07-03 | — | — | US | disclosed |
| EP-1316610-A1 | Preparation comprising an enzyme for asymmetrical hydrolysis of N-substituted C3-C4 cyclic imino-2-carboxylic acid ester and method of using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-06-04 | — | — | EP | disclosed |
| US-6537790-B1 | Isolated protein of given sequence which can produce N-substituted cyclic imino acids by hydrolization | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-03-25 | — | — | US | disclosed |
| US-20020173013-A1 | Esterace genes and uses of the same | SUMITOMO CHEMICAL COMPANY, LIMITED | 2002-11-21 | — | — | US | disclosed |
| EP-1057894-A2 | Esterase genes and uses of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-12-06 | — | — | EP | disclosed |
| US-4190579-A | Synthesis of beta-lactams from azetidine carboxylic acid esters | RESEARCH CORPORATION (US) | 1980-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173013-A1 | Esterace genes and uses of the same | ACOT7, COASY, IMPA1 | SMN1; SMN2 4145/4885FKBP1A 800/4885TP53 4061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.